Aclaris Therapeutics (ACRS) Short term Debt (2017)
Aclaris Therapeutics (ACRS) recorded quarterly Short term Debt of $590000.0 in Q4 2017.
Aclaris Therapeutics (ACRS) Short term Debt (2017) Analysis & Trends
Aclaris Therapeutics' Short term Debt history runs 1 years deep, the most recent figure standing at $590000.0 for Q4 2017.
- In Q4 2017, Short term Debt changed N/A year-over-year to $590000.0; the TTM figure through Dec 2017 stood at $590000.0 (changed N/A YoY), while the FY2017 annual figure was $590000.0, changed N/A from the prior year.
- Short term Debt was $590000.0 for Q4 2017 at Aclaris Therapeutics.
- In the past five years, Short term Debt ranged from a high of $590000.0 in Q4 2017 to a low of $590000.0 in Q4 2017.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Aclaris Therapeutics | 580.93 Mn | 580.93 Mn | 1.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | 590,000.00 |